证券代码：838275 证券简称：驱动力 公告编号：2024-053 广东驱动力生物科技集团股份有限公司 投资者关系活动记录表 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、投资者关系活动类别 □特定对象调研 □ 分析师会议 □ 媒体采访 √ 业绩说明会 □ 新闻发布会 □ 路演活动 □ 现场参观 □ 其他 （请文字说明其他活动内容） 二、投资者关系活动情况 （一）活动时间、地点 本次年度报告业绩说明会于 2024年5 月13日（星期一）15:00-17:00采 ...

关于对广东驱动力生物科技集团 股份有限公司问询函的回复 大华核字【2024】0011012415 号 大 华 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) Da Hua Certified PublicAccountants（Special General Partnership） 关于对广东驱动力生物科技集团股份有限公司 问询函的回复 目 录 页 次 一、 关于对广东驱动力生物科技集团股份有限公 司问询函的回复 1-14 大华会计师事务所（特殊普通合伙） 北京市海淀区西四环中路 16 号院 7 号楼 12 层 [100039] 电话：86 (10) 5835 0011 传真：86 (10) 5835 0006 www.dahua-cpa.com 关 于 对 广 东 驱 动 力 生 物 科 技 集 团 股 份 有 限 公 司 问 询 函 的 回 复 大华核字【2024】0011012415 号 北京证券交易所上市公司管理部： 大华会计师事务所（特殊普通合伙）（以下简称"年审会计师"、 "我们"）作为广东驱动力生物科技集团股份有限公司（以下简称"公 司"或"驱动力公司"）2023 年度的财务审计机构，已 ...

华安证券股份有限公司关于广东驱动力牛物科技集团 股份有限公司《问询函》有关事项的核查意见 北京证券交易所上市公司管理部: 华安证券股份有限公司(以下简称"华安证券"或"我司")作为广东驱动 力生物科技集团股份有限公司(以下简称"驱动力"或"公司")的持续督导券 商,于2024年4月29日收到贵部《关于对广东驱动力生物科技集团股份有限公 司的问询函》(问询函【2024】第014号)(以下简称"《问询函》"),我司持续督 导工作人员针对《问询函》中的相关事项进行了核查,并出具本核查意见。 一、涉及会计差错更正的相关业务历史上的具体开展情况、内容以及金额, 公司开展相关业务的原因及考虑,是否有助于提升公司的核心竞争力和盈利能 力,以及公司对该业务的定位及未来的规划安排。 (一)针对公司开展相关业务情况的核查 1、公司历史上开展相关业务(造血系列3)的原因及考虑 驱动力主营业务是研发、生产、销售具有提升动物造血能力的添加剂及添加 剂预混料、其他功能的添加剂预混料及全价配合饲料等(如下图所示)。公司产 品主要包括造血系列1(饲料添加剂)、造血系列2(预混合饲料)和造血系列 3 (全价配合饲料)等产品,公司的客户主要包括 ...

北京证券交易所上市公司管理部： 广东驱动力生物科技集团股份有限公司(以下简称"公司")于 2024 年 4 月 29 日收到北京证券交易所上市公司管理部下发的《关于对广东驱动力生物科技 集团股份有限公司的问询函》（【2024】第 014 号，以下简称"问询函"），公司董 事会高度重视，立即组织相关部门、人员就问询函中相关问题进行了认真核查并 落实。现对问询函所列问题回复如下： 证券代码：838275 证券简称：驱动力 公告编号：2024-050 广东驱动力生物科技集团股份有限公司 关于对北京证券交易所问询函回复的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 问题一： 补充历史上相关业务的具体开展情况、内容以及金额，并说明公司开展相 关业务的原因及考虑，是否有助于提升公司的核心竞争力和盈利能力，以及公 司对该业务的定位及未来的规划安排； 回复： （一）历史上开展相关业务（造血系列 3 全价配合饲料）的原因及考虑 公司主营业务是研发、生产、销售具有提升动物造血能力的添加剂及添加剂 预混料和全价配合饲 ...

广东驱动力生物科技集团股份有限公司(以下简称"公司")于 2024 年 4 月 29 日收到北京证券交易所上市公司管理部下发的《关于对广东驱动力生物科技 集团股份有限公司的问询函》（【2024】第 014 号，以下简称"问询函"），要求公 司就《问询函》相关事项做出书面说明，并在 2024 年 5 月 9 日前将有关说明材 料报送北京证券交易所上市公司管理部并对外披露。 公司收到《问询函》后积极会同相关中介机构对《问询函》中涉及的问题进 行逐项落实与回复。鉴于《问询函》部分问题的回复尚需进一步论证、补充和完 善，为确保回复内容的真实、准确和完整，经向北京证券交易所申请，公司将延 期至 2024 年 5 月 13 日前完成回复工作，并及时履行信息披露义务，敬请广大 投资者谅解。 特此公告。 广东驱动力生物科技集团股份有限公司 董事会 2024 年 5 月 9 日 证券代码：838275 证券简称：驱动力 公告编号：2024-049 广东驱动力生物科技集团股份有限公司 关于延期回复北京证券交易所问询函的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的 ...

关于对广东驱动力生物科技集团股份有限公司 的问询函 合同的主要内容、收入确认政策等，说明前期进行收入确认、审计后 又调减的依据及合理性，是否存在虚增收入的情形； 3.请公司自查相关更正事项是否涉及以前年度财务数据的更正， 并说明公司会计核算、财务制度和内部控制是否存在重大缺陷及拟采 取的改善措施，是否能够保证公司财务数据真实、准确、完整； 2024 年 4 月 29 日，你公司披露《业绩快报修正公告》，对业绩 快报中的财务数据进行修正。营业收入从 14,003.29 万元调整为 9,347.46 万元，调减金额 4,655.83 万元，调减比例为 33.25%。你公司 解释业绩修正主要原因为根据《企业会计准则》的相关规定及要求， 基于谨慎性原则，公司对部分销售合同的收入确认方法采用由总额法 调整为净额法，对部分销售合同的收入进行重新确认。 公司与年报同步披露的《前期会计差错更正公告》显示，公司 对部分业务的收入确认方法采用由总额法调整为净额法，并对 2023 年第三季度、2023 年半年度、2023 年第一季度、2022 年年度及 2021 年度相关财务数据进行了会计差错更正。 请你公司： 1. 补充历史上相 ...

1. 补充历史上相关业务的具体开展情况、内容以及金额，并说明公司开展 相关业务的原因及考虑，是否有助于提升公司的核心竞争力和盈利能力，以及 公司对该业务的定位及未来的规划安排； 证券代码：838275 证券简称：驱动力 公告编号：2024-048 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法 律责任。 广东驱动力生物科技集团股份有限公司(以下简称"公司"于 2024 年 4 月 29 日收到北京证券交易所上市公司管理部下发的《关于对广东驱动力生物科技 集团股份有限公司的问询函》(问询函【2024】第 014 号(以下简称" 《问询函》")， 现将《问询函》内容公告如下： 广东驱动力生物科技集团股份有限公司（驱动力）董事会、华安证券股份 有限公司、大华会计师事务所（特殊普通合伙）： 2024 年 4 月 29 日，你公司披露《业绩快报修正公告》，对业绩快报中的财 务数据进行修正。营业收入从 14,003.29 万元调整为 9,347.46 万元，调减金额 4,655.83 万元，调减比例为 33.25%。你公司解 ...

Financial Performance - The company reported a revenue of ¥51,329,621.47, an increase of 9.44% compared to the same period last year[13] - The net profit attributable to shareholders, after deducting non-recurring gains and losses, was ¥3,218,083.53, reflecting a growth of 48.98% year-on-year[13] - The company's operating revenue for the reporting period was 82,042,133.18, an increase of 27.73% compared to the previous year[19] - The company reported a net profit of 3,011,597.36, a decrease of 51.01% compared to the previous year, primarily due to a lack of government subsidies received last year[22] - The total revenue for the reporting period was ¥51,329,621.47, reflecting a growth of 9.42% compared to the previous period[42] - The total revenue for the first half of 2023 was CNY 82,042,133.18, an increase from CNY 64,232,221.91 in the same period of 2022, representing a growth of approximately 27.7%[47] - The net profit for the first half of 2023 was CNY 1,059,673.99, a significant decrease from a net loss of CNY 682,378.97 in the same period of 2022[46] Profitability Metrics - The gross profit margin decreased to 24.72% from 27.87% in the previous year[5] - The gross profit margin decreased to 15.46%, down 4.89 percentage points year-on-year, attributed to changes in product sales structure[19] - The gross profit margin for self-produced products decreased by 5.39 percentage points to 14.87%[32] - The gross profit margin for the overall business was 15.46%, down 4.89 percentage points from the previous year[38] - The operating profit was 3,090,234.36, down 18.01% year-on-year, influenced by a downturn in the downstream livestock industry[21] Operating Efficiency - The net cash flow from operating activities was ¥1,999,325.39, down 92.60% from ¥27,011,084.65 in the previous year[9] - The accounts receivable turnover rate improved to 1.99 from 1.19 year-on-year[9] - The inventory turnover rate increased to 3.47 from 2.58 in the previous year[9] - The credit impairment loss increased by 429.46% to -806,471.23, due to an increase in accounts receivable and the need to provision for bad debts[19] Revenue Sources - Revenue from blood products is $48,984,385.33, compared to $36,728,640.76 in the previous period, reflecting a significant increase of approximately 33.3%[57] - Revenue from stress-resistant and appetite-inducing products decreased to $913,841.93 from $2,133,811.87, a decline of about 57.1%[57] - Revenue from technical services decreased to $116,428.00 from $1,224,145.00, a decline of about 90.5%[57] - Other business revenue increased by 21.80% to ¥93,209.02, up from ¥76,529.15[31] Strategic Initiatives - The company launched cost-reduction products for livestock farmers in response to market pressures[12] - New departments were established, including ruminant, e-commerce, aquaculture, and regional divisions, to enhance market expansion[12] - The company aims to expand its product matrix to include aquaculture and pet sectors, leveraging its patented blood product technology[15] - The company plans to expand its market presence and invest in new product development to drive future growth[46] - The company has identified strategic opportunities for mergers and acquisitions to enhance its competitive position in the market[46] Other Financial Metrics - Other income increased significantly by 725.41% to 300,210.70, mainly due to government rewards received during the period[21] - Investment income rose to 2,482,029.52, a 145.04% increase, driven by higher returns from associated companies and increased interest from large time deposits[21] - Research and development expenses for the first half of 2023 were CNY 2,137,582.81, slightly down from CNY 2,293,360.29 in the first half of 2022, reflecting a decrease of about 6.8%[47] - The total assets of the company were reported at CNY 81,864,563.44, with net assets amounting to CNY 10,739,638.46[46] Market Position - The company maintains a leading position in the industry, supported by strong brand recognition and technological advancements[15] - The sales structure of the new product series accounted for 75.17% of total sales, contributing to the decline in gross margin[38] - Revenue from the Northeast region increased by 215.13% to ¥1,709,073.60, while the gross margin was 49.47%[41] Miscellaneous - The company expressed apologies for any inconvenience caused by the corrections made to the financial report[58] - The company has not disclosed any new product launches or technological advancements during this reporting period[58] - There are no updates on market expansion or mergers and acquisitions mentioned in the conference call[58]

Financial Performance - The company's revenue for 2022 was corrected to ¥97,072.53 million, a decrease of 28.62% compared to 2021[6]. - The net profit attributable to shareholders for 2022 was corrected to ¥17,399.34 million, reflecting a decrease of 56.52% year-over-year[10]. - The gross profit margin for 2022 was adjusted to 30.56%, down from 43.98% in 2021[6]. - The basic earnings per share for 2022 was corrected to ¥0.11, a decline of 56% compared to ¥0.25 in 2021[5]. - The overall operating profit margin was reported at 12.4%, down from 31.3% in the previous year[19]. - The operating profit for the reporting period was 19.19 million, a decrease of 55.43% compared to 2021, primarily due to a smaller increase in main business income compared to the increase in operating costs[24]. - The net profit for the reporting period was 17.38 million, a decrease of 56.56% compared to 2021, influenced by multiple factors[24]. - The company reported a net profit margin impacted by increased R&D expenses and operational costs[58]. - Total operating revenue for 2022 was 97,072,539, a decrease of 28.5% compared to 135,985,501 in 2021[60]. - Net profit for 2022 was 17,382,063, representing a decline of 56.6% from 40,017,018 in 2021[62]. Cash Flow - The net cash flow from operating activities for 2022 was ¥54,469.48 million, an increase of 112% from ¥25,658.46 million in 2021[8]. - The net cash flow from operating activities was 54,469.5 million, an increase of 112.29% compared to the previous year, driven by higher sales cash ratios[35]. - The net cash flow from investing activities was -21,838.7 million, an increase of 68.51% year-on-year, mainly due to reduced fixed asset investments[35]. - The net cash flow from financing activities was -49,349.2 million, a decrease of 245.05% compared to the previous year, attributed to the absence of external financing in 2022[35]. Operating Costs and Expenses - Operating costs amounted to 67,410,728 yuan, reflecting a decrease of 11.51% from 76,174,676 yuan in the previous year[19]. - Sales expenses were 10,897,595 yuan, a reduction of 15.18% compared to 12,847,418 yuan in the previous year[19]. - The operating cost for the reporting period was 67.18 million, a decrease of 11.58% compared to 2021, mainly due to reduced sales volume of blood products[25]. - Research and development expenses increased by 19.23% to 4,749,646 yuan from 3,983,697 yuan in the previous year[19]. Revenue Sources - The revenue from hematopoietic products was 84,102.3 million, a decrease of 8.55% compared to the same period in 2021[32]. - The revenue from other products was 12,970.2 million, a decrease of 70.54% year-on-year, primarily due to a reduction in various feed materials and technical service fees[31]. - Revenue from blood products was 79,906,522.33, down from 89,420,301.90 in the previous period[64]. - Revenue from stress-resistant and appetite-inducing products was 4,195,808.87, an increase from 2,543,664.50 in the previous period[64]. - Revenue from concentrated feed and additives was 8,702,552.93, down from 30,976,376.37 in the previous period[64]. Audit and Compliance - The company identified revenue recognition as a key audit matter due to the inherent risk of management manipulating revenue recognition timing[48]. - The company has implemented significant audit procedures to evaluate the effectiveness of internal controls related to revenue recognition[49]. - The company's revenue recognition policy aligns with accounting standards, ensuring compliance[55]. - The company’s management has been proactive in addressing potential risks associated with revenue recognition practices[48]. Subsidiaries and Investments - The company has four wholly-owned subsidiaries, one controlling subsidiary, and one associated company as of December 31, 2022[42]. - Guangzhou Sanhang Biotechnology Co., Ltd. generated revenue of 3.76 million yuan and a net profit of 0.55 million yuan during the reporting period[42]. - Guangzhou Sanhang Feed Co., Ltd. achieved revenue of 11.83 million yuan and a net profit of 0.87 million yuan[45]. - Guangdong Sanhang Biotechnology Co., Ltd. reported revenue of 37.09 million yuan and a net profit of 0.31 million yuan[45]. - Guangzhou Saitao Flower Biotechnology Co., Ltd. generated revenue of 2.56 million yuan and a net profit of 1.37 million yuan[45]. - Guangdong Sanhang Blood Feed Co., Ltd. reported a net loss of 0.035 million yuan during the reporting period[43]. - Guangdong Xinnandu Feed Technology Co., Ltd. achieved revenue of 55.96 million yuan and a net profit of 5.46 million yuan[45]. Management Commentary - The company expressed apologies for any inconvenience caused by the corrections made in the financial report[65]. - The company plans to expand its market presence and enhance product offerings through new technology development and strategic partnerships[30].

Financial Performance - Net profit attributable to shareholders was CNY 1,007,104.04, down 51.40% year-on-year[12]. - Operating income for the period was CNY 25,990,213.95, a decrease of 5.70% compared to the same period last year[12]. - The company's weighted average return on net assets attributable to shareholders was 0.43%, down from 0.78% in the previous year[10]. - Total operating revenue for Q1 2023 was ¥25,990,213.95, a decrease of 5.7% from ¥27,561,364.26 in Q1 2022[56]. - Net profit for Q1 2023 was ¥978,994.81, down 52.8% from ¥2,072,317.04 in Q1 2022[57]. - The company's operating profit for Q1 2023 was ¥995,316.30, compared to ¥2,232,202.96 in Q1 2022, reflecting a decrease of 55.5%[56]. - The total profit for Q1 2023 was ¥995,316.30, compared to ¥2,224,783.73 in Q1 2022, indicating a decrease of 55.4%[57]. - The company reported investment income of ¥152,837.78 in Q1 2023, down from ¥342,850.02 in Q1 2022, a decline of 55.5%[56]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 251,814,357.83, a decrease of 0.07% compared to the end of the previous year[10]. - The company's asset-liability ratio (consolidated) was 7.05%, down from 7.51% at the end of the previous year[10]. - Total liabilities decreased from CNY 18,927,763.76 to CNY 17,757,123.70, a decline of about 6.2%[50]. - Current liabilities decreased from CNY 18,844,125.25 to CNY 17,673,485.19, a reduction of approximately 6.2%[49]. - The total non-current assets increased to ¥146,311,978.53 from ¥125,815,982.62, showing an increase of approximately 16.3%[48]. - The company's debt investment increased significantly to ¥121,398,282.53 from ¥101,020,670.90, representing a growth of about 20.2%[48]. Cash Flow - Net cash flow from operating activities increased by 307.16% to CNY 2,737,745.79 due to increased product sales and improved collection efforts[14]. - Operating cash inflow for Q1 2023 reached ¥54,665,244.60, a significant increase from ¥29,758,286.00 in Q1 2022, representing an 83.6% growth[61]. - Net cash flow from operating activities for Q1 2023 was ¥2,737,745.79, compared to ¥672,398.83 in Q1 2022, indicating a substantial improvement[62]. - Cash outflow from investment activities in Q1 2023 totaled ¥27,377,925.67, up from ¥23,558,734.64 in Q1 2022, reflecting increased investment efforts[62]. - The net increase in cash and cash equivalents for Q1 2023 was -¥2,613,054.90, contrasting with an increase of ¥24,272,682.04 in Q1 2022, signaling a challenging financial environment[62]. Shareholder Information - The total number of ordinary shareholders was 4,773 at the end of the reporting period[17]. - Liu Jinping and Liu Pingxiang hold 33.2348% and 21.9104% of the shares respectively, together controlling 55.1452% of the voting rights of the company[21]. - The total number of shares held by the top ten shareholders is 122,434,054, accounting for 76.3888% of the total shares[21]. - The largest shareholder, Liu Jinping, has a total of 53,268,016 shares, which is 33.2348% of the total shares[18]. - The company has a total of 70,083,206 shares that are not subject to any restrictions[21]. Compliance and Commitments - The company has committed to avoiding related party transactions and has not engaged in any such transactions during the reporting period[31][35]. - The actual controller has provided a commitment to avoid any competition with the company, ensuring no direct or indirect involvement in similar business activities[29][30]. - The company has committed to strict compliance with regulations regarding social insurance and housing funds, with a plan to increase awareness among employees[33][34]. - The company has established a framework for new commitments in case of non-fulfillment, which will be subject to shareholder approval[43]. - The company will comply with all relevant regulations regarding share reduction and disclosure obligations[37]. Operational Efficiency - The company plans to focus on market expansion and new product development in the upcoming quarters[60]. - Cash inflow from other operating activities in Q1 2023 was ¥11,842,880.77, a significant rise from ¥422,665.75 in Q1 2022, indicating enhanced operational efficiency[61]. - Research and development expenses decreased to ¥706,165.48 in Q1 2023 from ¥885,122.06 in Q1 2022, a reduction of 20.2%[56].